A method for data‐driven exploration to pinpoint key features in medical data and facilitate expert review. Issue 10 (16th August 2017)

• Record Type: Journal Article
• Authors: Juhlin, Kristina; Star, Kristina; Norén, G. Niklas
• Is Part Of: Pharmacoepidemiology and drug safety. Volume 26:Issue 10(2017)
• Page Start: 1256
• Page End: 1265
• Publication Date: 2017-08-16
• Subjects: exploratory analysis -- individual case safety reports -- medication errors -- odds ratios -- pharmacoepidemiology -- statistical shrinkage; Pharmacoepidemiology -- Periodicals; Chemotherapy -- Periodicals; Epidemiology -- Periodicals; 615.705
• DOI: 10.1002/pds.4285
• Languages: English
• ISSNs: 1053-8569

Abstract

Abstract: Purpose: To develop a method for data‐driven exploration in pharmacovigilance and illustrate its use by identifying the key features of individual case safety reports related to medication errors. Methods: We propose vigiPoint, a method that contrasts the relative frequency of covariate values in a data subset of interest to those within one or more comparators, utilizing odds ratios with adaptive statistical shrinkage. Nested analyses identify higher order patterns, and permutation analysis is employed to protect against chance findings. For illustration, a total of 164 000 adverse event reports related to medication errors were characterized and contrasted to the other 7 833 000 reports in VigiBase, the WHO global database of individual case safety reports, as of May 2013. The initial scope included 2000 features, such as patient age groups, reporter qualifications, and countries of origin. Results: vigiPoint highlighted 109 key features of medication error reports. The most prominent were that the vast majority of medication error reports were from the United States (89% compared with 49% for other reports in VigiBase); that the majority of reports were sent by consumers (53% vs 17% for other reports); that pharmacists (12% vs 5.3%) and lawyers (2.9% vs 1.5%) were overrepresented; and that there were more medication error reports than expected for patients aged 2‐11 years (10% vs 5.7%), particularly in Germany (16%). Conclusions: vigiPoint effectively identified key features of medication error reports in VigiBase. More generally, it reduces lead times for analysis and ensures reproducibility and transparency. An important next step is to evaluate its use in other data.